270 related articles for article (PubMed ID: 24158967)
1. Emerging treatments in recurrent and metastatic colorectal cancer.
Ciombor KK; Bekaii-Saab T
J Natl Compr Canc Netw; 2013 Sep; 11 Suppl 4(Suppl 4):S18-27. PubMed ID: 24158967
[TBL] [Abstract][Full Text] [Related]
2. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
3. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
6. Role of targeted agents in metastatic colorectal cancer.
Prenen H; Vecchione L; Van Cutsem E
Target Oncol; 2013 Jun; 8(2):83-96. PubMed ID: 23645285
[TBL] [Abstract][Full Text] [Related]
7. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
9. Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
Temraz S; Mukherji D; Shamseddine A
World J Gastroenterol; 2014 Feb; 20(8):1993-2004. PubMed ID: 24616571
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.
Ciombor KK; Bekaii-Saab T
Oncologist; 2018 Jan; 23(1):25-34. PubMed ID: 29021377
[TBL] [Abstract][Full Text] [Related]
11. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.
Bekaii-Saab T; Wu C
Crit Rev Oncol Hematol; 2014 Jul; 91(1):9-34. PubMed ID: 24534706
[TBL] [Abstract][Full Text] [Related]
12. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
13. [Target Therapy in Unresectable or Metastatic Colorectal Cancer].
Kim JH; Park SJ
Korean J Gastroenterol; 2016 Dec; 68(6):303-311. PubMed ID: 28025473
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives.
Marques I; Araújo A; de Mello RA
World J Gastroenterol; 2013 Nov; 19(44):7955-71. PubMed ID: 24307789
[TBL] [Abstract][Full Text] [Related]
15. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
16. Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
[TBL] [Abstract][Full Text] [Related]
17. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
18. Options for Second-Line Treatment in Metastatic Colorectal Cancer.
Lee JJ; Sun W
Clin Adv Hematol Oncol; 2016 Jan; 14(1):46-54. PubMed ID: 27057668
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
20. The role of targeted therapy in the treatment of advanced colorectal cancer.
Fakih M
Curr Treat Options Oncol; 2008 Dec; 9(4-6):357-74. PubMed ID: 19238551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
